会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Hard butter composition and its production
    • 硬黄油组成及其生产
    • US06258398B1
    • 2001-07-10
    • US09533588
    • 2000-03-23
    • Tadayuki OkadaKazuhisa YamadaAtsushi Nago
    • Tadayuki OkadaKazuhisa YamadaAtsushi Nago
    • A23D9013
    • A23G1/36A23D9/013A23G1/38C11B7/0008C11B7/0075
    • A hard butter composition is described that comprises 50 to 80% by weight of SUS type triglycerides, less than 2% by weight of SSS type triglycerides and at least 1% by weight of a polyglycerol fatty acid ester (wherein S's are saturated fatty acid residues which are substantially palmitic acid and/or stearic acid residues and U's are unsaturated fatty acid residues which are substantially C16 and/or C18 unsaturated fatty acids). The composition further comprises SSU type triglycerides in an amount of at least 15% by weight based on the total amount of SUS type triglycerides and SSU type triglycerides. The hard butter composition is a non-tempering type hard butter composition having good meltability in the mouth, which is free from trans acids and lauric acid. A process for producing the hard butter composition is also disclosed.
    • 描述了一种硬质黄油组合物,其包含50至80重量%的SUS型甘油三酯,小于2重量%的SSS型甘油三酯和至少1重量%的聚甘油脂肪酸酯(其中S是饱和脂肪酸残基 其基本上是棕榈酸和/或硬脂酸残基,U是基本上为C16和/或C18不饱和脂肪酸的不饱和脂肪酸残基)。 所述组合物还包含基于SUS型甘油三酯和SSU型甘油三酸酯的总量的至少15重量%的SSU型甘油三酯。 硬质黄油组合物是在口中具有良好熔融性的无回火型硬质黄油组合物,其不含反式酸和月桂酸。 还公开了生产硬质黄油组合物的方法。
    • 5. 发明申请
    • AGENT FOR REDUCING RISK IN ONSET OF DISEASE ASCRIBABLE TO NON-DIPPER CIRCADIAN RHYTHM OF BLOOD PRESSURE
    • 减少患有血液循环不良风险的药物的代理人
    • US20120115786A1
    • 2012-05-10
    • US13292561
    • 2011-11-09
    • Mari TAKAHASHINaoyuki YamamotoKazuhisa YamadaToshirou Iketani
    • Mari TAKAHASHINaoyuki YamamotoKazuhisa YamadaToshirou Iketani
    • A61K38/06A61P9/00
    • A61K38/018A61K38/06
    • An agent for reducing risk in onset of diseases ascribable to non-dipping circadian profile of blood pressure is provided. This agent is capable of effectively lowering SBP from night to early morning in individuals with non-dipping circadian profile of blood pressure, in particular, normal individuals with normal SBP and DBP among them, and is thus capable of reducing risk in onset, particularly likely in the morning, of diseases caused by circadian variation of blood pressure. The agent is intended for administration to such subjects, and contains a hydrolysate or a concentrate thereof, containing Val-Pro-Pro and Ile-Pro-Pro and obtained by hydrolysis of animal milk protein. Reduction of risk may be expected in onset, particularly likely in the morning, of various diseases caused by risk of circadian variation of blood pressure, such as cerebral infarction, myocardial infarction,myocardialischemia, atherosclerosis, cardiac failure, cerebral stroke, coronary artery diseases, and peripheral vascular diseases.
    • 本发明提供一种减轻由于血压异常昼夜节律引起的疾病发病风险的药剂。 该药物能够在夜间至清晨有效降低血压非溺水昼夜状况的个体,特别是其中正常的SBP和DBP的正常个体,因此能够降低起病风险,特别可能 早晨,由血压昼夜变化引起的疾病。 该试剂用于给予这些受试者,并含有含有Val-Pro-Pro和Ile-Pro-Pro并通过动物乳蛋白水解获得的水解产物或其浓缩物。 可能预期,由于血压昼夜变化风险,如脑梗死,心肌梗塞,心肌缺血,动脉粥样硬化,心力衰竭,脑卒中,冠状动脉疾病等引起的各种疾病,特别是早晨发病风险的降低, 和外周血管疾病。